E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
SARS-CoV-2 infection (only mild to moderate disease) |
SARS-CoV-2 Infektion mit leichten oder mildem Krankheitsbild |
|
E.1.1.1 | Medical condition in easily understood language |
COVID-19 (only mild to moderate disease) |
COVID-19 mit leichten oder mildem Krankheitsbild |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084272 |
E.1.2 | Term | SARS-CoV-2 infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate the safety and tolerability of a single inhaled application of DZIF-10c in SARS-CoV-2-uninfected and SARS-CoV-2-infected individuals. - To evaluate the safety and tolerability of a single combined inhaled and intravenous application of DZIF-10c in SARS-CoV-2-infected individuals.
|
|
E.2.2 | Secondary objectives of the trial |
All to be determined after a single inhaled application of DZIF-10c or a single combined inhaled and intravous application of DZIF-10c:
- To determine the systemic DZIF-10c exposure (AUC0-672h (i.e., from the day 0 to the day 28 visit)). - To determine the development of antibodies targeting DZIF-10c (anti-drug antibodies, ADA)- - To determine the effect of DZIF-10c on SARS-CoV-2 shedding in nasopharyngeal swabs by qRT-PCR
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Groups 1A-1C - Age 18 to 65. - SARS-CoV-2-RNA negative naso- or oropharyngeal swab obtained within 3 calendar days before study drug administration by NAAT (e.g., qRT-PCR). - Non-reactivity of serum antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological assay at screening.
Groups 2C-2D - Age 18 to 70. - SARS-CoV-2-RNA positive naso- or oropharyngeal swab obtained within 3 calendar days before study drug administration by NAAT (e.g., qRT-PCR). - Onset of COVID-19 symptoms (e.g., sore throat, cough, fever, chills, fatigue, dys- or anosmia, dys- or angeusia, headache, muscle pain, gastrointestinal symptoms) within 7 days prior to study drug administration or Non-reactivity of serum or plasma antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological assay at screening. - Disease severity score 1-4 as defined by the WHO Clinical Progression Scale (WHO, Lancet Inf Dis 2020)
|
|
E.4 | Principal exclusion criteria |
- Known hypersensitivity to any constituent of the investigational medicinal product. - Hepatitis B infection indicated by detectable HBsAg (Hepatitis B surface antigen) in blood. - Detectable antibodies against hepatitis C virus in blood unless active hepatitis C is ruled out by negative HCV-RNA. - HIV infection indicated by detectable HIV antigen and/or HIV antibodies in blood. - Blood laboratory parameter abnormalities as listed below - Neutrophil count ≤1,000 cells/µl - Hemoglobin ≤10 g/dl - Platelet count ≤100,000 cells/µl - ALT ≥2.0 x ULN - AST ≥2.0 x ULN - Total bilirubin ≥1.5 ULN - eGFR <60 ml/min/1.73m2 - Pregnancy or lactation. - Any vaccination within 14 days prior to DZIF-10c administration. - Receipt of any SARS-CoV-2 vaccine or SARS-CoV-2 monoclonal antibody in the past. - Diagnosis of bronchial asthma or history of bronchial hyperresponsiveness, COPD, pulmonary fibrosis, or other chronic lung diseases. - Any chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer. - History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months (a single administration of systemic corticosteroids within ≤6 months and ≥4 weeks of enrollment is acceptable). - Participation in another clinical trial of an investigational medicinal product within the past 12 weeks or expected participation during this study. - Dependency on the principal investigator or study staff; or site personnel directly affiliated with this trial. - Legally incapacitated individuals - Individuals held in an institution by legal or official order - If engaging in sexual activity that could result in pregnancy, inability or unwilligness to comply with the requirements for highly effective contraception |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- The rate of Adverse Events after DZIF-10c inhalation. - The rate of Adverse Events after the combined inhalation and intranveous infusion of DZIF-10c.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- The dose limiting toxicity (DLT) period comprises the first 7 days after DZIF-10c inhalation, adverse events until end of follow up period (90 day after treatment with DZIF-10c) - The dose limiting toxicity (DLT) period comprises the first 7 days after the combined inhalation and intranveous infusion of DZIF-10c, adverse events until end of follow up period (90 day after treatment with DZIF-10c) |
|
E.5.2 | Secondary end point(s) |
To be determined after a single inhaled application of DZIF-10c or a single combined inhaled and intravenous application of DZIF-10c: - The Area under the Curve (AUC) for DZIF-10c levels from the day 0 to the day 28 visit (AUC0-672h) - The frequency and magnitude of anti-drug antibodies targeting DZIF-10c. - SARS-CoV-2 RNA shedding in nasopharyngeal swabs determined by qRT-PCR in SARS-CoV-2-infected individuals
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
1) open-label dose-escalation phase, 2 ) Randomized double-blind placebo-controlled phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |